17

ImmunoGen, Inc. (NASDAQ: IMGN) went up by 1.94% from its latest closing price when compared to the 1-year high value of $12.31, while IMGN stocks collected -2.48% of loss with the last five trading sessions.

ImmunoGen, Inc. (NASDAQ: IMGN) Worth an Investment?

ImmunoGen, Inc. (NASDAQ: IMGN) The 36 Months beta value for IMGN stocks is at 1.92, while 6 of the analysts out of 10 who provided ratings for ImmunoGen, Inc. stocks as a “buy” while 0 as overweight, 3 rated it as hold and 1 as sell. The average price we get from analysts is $5.29 which is $2.14 above current price. IMGN currently has a short float of 8.75% and public float of 147.02M with average trading volume of 3.62M shares.

IMGN Market Performance

IMGN stocks went down by -2.48% for the week, with the monthly jump of 17.54% and a quarterly performance of -41.23%, while its annual performance rate touched -70.31%. The simple moving average for the period of the last 20 days is 15.43% for IMGN stocks with the simple moving average of -45.58% for the last 200 days.

Analysts’ Opinion on ImmunoGen, Inc. (NASDAQ: IMGN)

Many brokerage firms have already submitted their reports for IMGN stocks, with H.C. Wainwright repeating the rating for IMGN shares by setting it to “Buy”. The predicted price for IMGN socks in the upcoming period according to H.C. Wainwright is $7 based on the research report published on May 6, 2019.

Cowen, on the other hand, stated in their research note that they expect to see IMGN stock at the price of $7. The rating they have provided for IMGN stocks is “Outperform” according to the report published on May 6, 2019.

JP Morgan gave “ Underweight” rating to IMGN stocks, setting the target price at $7 in the report published on March 19, 2019.

IMGN Stocks 17.68% Far from 50 Day Moving Average

After a stumble in the market that brought IMGN to its low price for the period of the last 52 weeks, ImmunoGen, Inc. was unable to take a rebound, for now settling with -74.41% of loss for the given period.

The stock volatility was left at 7.76%, however, within the period of a single month, the volatility rate increased by 7.34%, while the shares surge at the distance of +14.96% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +21.15% upper at the present time.

In the course of the last 5 trading sessions, IMGN went down by -2.48%, which changed the moving average for the period of 200 days to the total of -68.34% of losses for the stock in comparison to the 20-day moving average settled at $2.75. In addition, ImmunoGen, Inc. saw -34.38% in overturn over the period of a single year with a tendency to cut further losses.

IMGN Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at ImmunoGen, Inc. (IMGN), starting from Gregory Richard J., who sold 3,038 shares at the price of $5.27 back on Jan 07. After this action, Rushing now owns 236,056 shares of ImmunoGen, Inc., valued at $16,014 with the latest closing price.

Goldberg Mark Alan, the Director of ImmunoGen, Inc., bought 30,000 shares at the value of $5.76 during a trade that took place back on Nov 06, which means that Goldberg Mark Alan is holding 53,800 shares at the value of $172,800 based on the most recent closing price.

IMGN Stock Fundamentals

The current profitability levels are settled at -295.17 for the present operating margin. The net margin for ImmunoGen, Inc. stands at -315.91. Total capital return value is set at -100.22, while invested capital returns managed to touch -124.53. Equity return holds the value -582.60%, with -51.90% for asset returns.

Based on ImmunoGen, Inc. (IMGN), the company’s capital structure generated 1,369.75 points for debt to equity in total, while total debt to capital is set at the value of 93.20. Total debt to assets is settled at the value of 50.88 with long-term debt to equity ratio rests at 1,133.88 and long-term debt to capital is 77.15.

The value for Enterprise to Sales is 8.78 with debt to enterprise value settled at 0.27. The receivables turnover for ImmunoGen, Inc. is 6.18 with the total asset turnover at the value of 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.95.